Figure 6
From: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
Maxatezo has stronger anti- tumor activity in vivo. MC38 cells were injected subcutaneously into C57BL/6 mice (n = 8). On day 7, the animals were randomly grouped and treated with Maxatezo (1 mg/kg, 10 mg/kg), Atezolizumab (10 mg/kg) and human IgG1 a control every 3 days. The plots show changes in tumor volume over time in Maxatezo-treated versus Atezolizumab-treated mice. The data are presented as mean ± SD. The horizontal coordinate represents the days after tumor inoculation and the vertical coordinate represents the tumor volume (mm3).
